CD274 and gastric cancer: Unfortunately, only a few patients are eligible for these new therapy options: the predictive biomarker Her2Neu is expressed in approximately 18% of AGE/S tumors [32], and about 28% of gastric cancer are eligible for checkpoint inhibition by having a sufficient PD-L1 expression with a combined positive score >5 [33].